NCT03668431 - Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

September 1, 2022

Study Completion Date

December 1, 2022

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Dabrafenib

"Dabrafenib will be taken twice a day for 28 consecutive days~."

DRUG

Trametinib

Trametinib will be taken once a day for 28 consecutive days

DRUG

PDR001

PDR001 will be administered IV every 28 days

Trial Locations (2)

RECRUITING

Massachusetts General Hosital Cancer Center, Boston

RECRUITING

Dana Farber Cancer Institite, Boston